Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd. develops therapies for severe neurodegenerative diseases, led by PrimeC, a proprietary fixed-dose oral extended-release combination of ciprofloxacin and celecoxib. Company news centers on PrimeC clinical and biomarker data in amyotrophic lateral sclerosis, Alzheimer’s disease program updates, regulatory interactions, and scientific publications or conference presentations related to the PARADIGM and PARAGON programs.
Recurring developments also include intellectual-property coverage for the PrimeC composition, including patent grants in Brazil, the United States and Australia, as well as Nasdaq listing compliance notices, shareholder voting matters, capital-structure disclosures, governance updates, material agreements, and operating or financial results.
NeuroSense (NASDAQ: NRSN) will present long-term survival data from the Phase 2b PARADIGM trial of PrimeC at the MDA Clinical & Scientific Conference on March 9, 2026. The analysis showed a 65% reduction in risk of death (HR 0.35; p=0.0037) and a >14-month median survival benefit (36.3 vs. 21.4 months; log-rank p=0.0218).
The randomized, double-blind, placebo-controlled study enrolled 68 participants (2:1 randomization) with a six-month double-blind period followed by an open-label extension; safety was described as favorable.
NeuroSense (NASDAQ: NRSN) reported extended PARADIGM Phase 2b survival data showing a median survival of 36.3 months with continuous PrimeC versus 21.4 months for initial placebo, an improvement of over 14 months (~70% increase).
Adjusted analysis showed a 65% reduction in risk of death (HR 0.35; 95% CI 0.17–0.71; p=0.0037) and a statistically significant log-rank p=0.0218. The randomized 68-patient trial included a 2:1 active:placebo double-blind period and an open-label extension; company engagement with regulators continues.
NeuroSense (Nasdaq: NRSN) announced that IP Australia granted Australian Patent No. 2022370513 for compositions comprising ciprofloxacin and celecoxib, extending patent protection for PrimeC through October 2042.
The grant follows a corresponding U.S. patent (12,097,185) and strengthens the company’s global exclusivity strategy as PrimeC advances toward pivotal Phase 3 development in ALS after positive Phase 2b PARADIGM results and FDA clearance of the Phase 3 protocol.
NeuroSense (NASDAQ: NRSN) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,527,768 for a PrimeC combination therapy for Alzheimer's disease, extending patent protection through 2043. The patent covers compositions combining an anti-inflammatory drug and a Dicer activator for neuronal diseases, which the company says strengthens its intellectual property for long-term development and potential commercialization.
NeuroSense also completed a proof-of-concept Alzheimer's study (RoAD) with top-line results showing a favorable safety and tolerability profile. Clinical and biomarker outcomes from the study are expected in Q1 2026.
NeuroSense (NASDAQ: NRSN) announced that Prof. Steven E. Arnold, a noted Alzheimer's expert and Professor of Neurology at Harvard Medical School, has joined its Scientific Advisory Board.
The company said Prof. Arnold brings biomarker-driven clinical development and translational neuroscience experience as NeuroSense advances its PrimeC programs in ALS and Alzheimer's disease. NeuroSense reported that its proof-of-concept Alzheimer's study (RoAD) showed a favorable safety and tolerability profile, and that clinical and biomarker outcomes from RoAD are expected in Q1 2026.
NeuroSense (NASDAQ: NRSN) reported completion of the safety analysis from its Phase 2 randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC in Alzheimer's disease on Dec 22, 2025.
The safety review found a favorable tolerability profile, with no serious adverse events reported and no new or unexpected safety signals identified. Clinical outcome measures in this exploratory proof-of-concept study are descriptive by design.
NeuroSense will analyze clinical observations together with biomarker data to aid interpretation, and full clinical and biomarker results are expected in Q1 2026.
NeuroSense (NASDAQ: NRSN) said it is resuming regulatory activity in Canada for PrimeC in amyotrophic lateral sclerosis (ALS) after a productive discussion with Health Canada.
Health Canada outlined remaining requirements and confirmed NeuroSense's proposed next steps align with the Agency's expectations. The company is preparing for a pre‑NDS meeting currently contemplated in April 2026. With additional clinical data recently generated and further analyses underway, NeuroSense said it anticipates a potential NDS submission by mid‑2026, pending a successful meeting and completion of final submission components.
NeuroSense will provide more details at an investor webinar on December 8, 2025.
NeuroSense (Nasdaq: NRSN) announced that the U.S. Food and Drug Administration completed review of its IND amendment and authorized initiation of the pivotal Phase 3 trial PARAGON evaluating PrimeC in amyotrophic lateral sclerosis (ALS) on Nov 24, 2025. PARAGON is planned as a global, double-blind, 12-month, placebo-controlled study with 300 participants randomized 2:1 (PrimeC:placebo), an open-label extension, an adaptive design with interim analyses, and is powered at >95% for its primary endpoint. NeuroSense aims to enroll the first patient in the coming months subject to securing strategic resources. Additional trial details and timelines will be presented at an investor webinar on Dec 8, 2025.
NeuroSense (NASDAQ: NRSN) will host an investor webinar on December 8, 2025 at 8:30 a.m. ET to provide business, regulatory and clinical updates.
Planned topics include the Phase 3 PARAGON study initiation (ALS), submission for Notice of Compliance with conditions (NOC/c) in Canada, the status of a binding term sheet executed in December 2024, and updates on the RoAD Phase 2 program (Alzheimer's disease). Investors can register to attend the webcast.
NeuroSense (NASDAQ: NRSN) reported Phase‑2b plasma biomarker results for PrimeC on October 6, 2025 showing statistically significant reductions in multiple Alzheimer's‑linked microRNAs. Key measured reductions from baseline include miR‑21‑5p (p=0.003), miR‑146a‑5p (p=0.007), miR‑let‑7e‑5p (p=0.006) and miR‑let‑7a‑5p (p=0.028), while placebo showed no significant changes over time. The company said these miRNA changes reflect reduced neuroinflammatory and neurodegenerative activity and support PrimeC's potential as a disease‑modifying therapy. NeuroSense indicated the data will inform design of a follow‑on Alzheimer's study and that Phase‑3 readiness for PrimeC in ALS remains ongoing.